The Danish pharmaceutical heavyweight is navigating a turbulent stretch, with its stock languishing roughly 46% below the June 2025 peak of €70.13. But a flurry of clinical updates and a multibillion-dollar share repurchase plan are offering investors something to rally behind as the second-quarter numbers approach.
Zenagamtide Delivers a Diabetes Breakthrough
Fresh from the American Diabetes Association meeting in New Orleans, Novo Nordisk unveiled striking Phase 2 data for Zenagamtide, the oral candidate formerly known as Amycretin. At the highest dose of 40 mg, patients with type 2 diabetes saw their HbA1c drop by 1.71 percentage points over 36 weeks. Nearly 89% crossed the clinically meaningful threshold of under 7%, while average body weight fell by 14.6%. The company expects to launch Phase 3 in the second half of 2026, with initial results unlikely before 2028.
CagriSema Marches Toward an FDA Verdict
Meanwhile, the spotlight remains on CagriSema, the combination therapy that could redefine Novo Nordisk’s obesity franchise. In the REDEFINE-1 study, the drug produced a mean weight loss of 22.7% after 68 weeks, comfortably outpacing semaglutide (16.1%) and cagrilintide alone (11.8%). The REIMAGINE-1 diabetes trial also met its goals, yielding a 2.33 percentage-point HbA1c reduction and 12.0% weight loss against placebo — results simultaneously published in The Lancet and The Lancet Diabetes & Endocrinology.
The road is not entirely smooth. In the head-to-head REDEFINE-4 trial against Eli Lilly’s tirzepatid, CagriSema achieved a 23% weight loss after 84 weeks but missed the primary endpoint of non-inferiority. Even so, Novo Nordisk anticipates a regulatory decision on the REIMAGINE program from the FDA in the fourth quarter of 2026 — a potential catalyst that could reframe the stock’s narrative.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Buyback Ramp and Cost Cuts Underpin the Stock
While the pipeline makes headlines, Novo Nordisk is quietly buying its own shares in size. Since February 4, it has repurchased nearly 18.8 million B-shares at an average price of 264.32 DKK, for a total outlay of roughly 5 billion DKK. The broader program runs to 15 billion DKK and is scheduled to continue until February 2027, with a current tranche of 11.2 billion DKK. The buyback has provided some support, though the stock closed Friday at €38.03 — still 8% below its 200-day moving average of €41.43 and down nearly 15% year to date.
The next major checkpoint is August 5, when Novo Nordisk is expected to release second-quarter results before the market opens. The first quarter offered a mixed picture: reported sales climbed 32% to 96.8 billion DKK, but adjusted revenue fell 4% after stripping out a large provision reversal. Net profit came in at 48.6 billion DKK. For the full year, management guided for an adjusted revenue decline of 4% to 12% at constant exchange rates, with operational headwinds from US most-favored-nation pricing agreements and intensifying competition from Eli Lilly and emerging biosimilars.
Leaner Operations and New Markets
The company is also executing a restructuring that will eliminate roughly 9,000 positions, generating annual savings of 8 billion DKK to be reinvested into R&D and commercial efforts from late 2026 onward. Meanwhile, plans for the oral Wegovy pill are advancing beyond the US, with a recent approval in the United Arab Emirates signaling international rollout. Free cash flow for 2026 is expected to land between 36 billion and 46 billion DKK, against planned capital expenditures of around 55 billion DKK.
With a busy pipeline, a supportive buyback, and a decisive FDA decision on the horizon, Novo Nordisk is walking a tightrope between near-term price pressure and long-term therapeutic potential. The August report will test whether the company’s operational pivot can begin to lift the shares off their lows.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from June 14 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 14.
Novo Nordisk: Buy or sell? Read more here...
